ClinicalTrials.gg
CompletedNCT06171113Updated Jul 8, 2026

A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants

A Phase 1 interventional study of GSK4024484C and Placebo in Malaria, Falciparum, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Malaria, Falciparum by GlaxoSmithKline — 3 open to participants now, 3 under way, none of them phase 3. Malaria, Falciparum · GlaxoSmithKline.

Enrollment
16th of 20
123 · median 410
Started
2023
the only one that year
Phase 1
4 of 21
1 open now
Registered
17th of 21
by date

Among the 21 studies in Malaria, Falciparum by GlaxoSmithKline, this one is the 16th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 1, and was the 17th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

3 of the 21 studies in Malaria, Falciparum by GlaxoSmithKline are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Malaria, Falciparum by GlaxoSmithKline, or all of them as a file.
02

Study summary

The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.

03

Conditions studied

  • Malaria, Falciparum

Browse trials for

Keywords

  • First time in human
  • Safety
  • Pharmacokinetics
  • GSK4024484
  • Healthy adults
  • Food effect
  • Single oral doses
  • Multiple oral doses
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be 18 to 60 years of age inclusive, at the time of signing the .
  2. Participants who are considered healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac assessment.
  3. A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, or outside the normal reference range for the population being studied, may be included only if the Investigator considers, that the finding is unlikely to introduce additional risk factors for the participant and will not interfere with the study procedures or endpoints.
  4. (Alanine transaminase) and AST (Aspartate transaminase) within the normal range at screening.
  5. Total within the normal range unless the participant is known to have Gilbert's syndrome.
  6. Body weight ≥50kg, and within the range 19 to 32 kilogram per square metre (kg/m\^2) inclusive.
  7. Male participants and female participants who are not of child bearing potential.
  8. The participant is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of cardiovascular (including hypertension), respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data in the opinion of the investigator.
  2. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  3. An average weekly alcohol intake of >14 units a week within 6 months prior to the study. One unit is equivalent to 8 g of alcohol: a half-pint (\~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
  4. (Fridericia's formula) >450 msec based on average of triplicate ECGs. The QTcF is the QT interval corrected for heart rate according to QTcF.
  5. More than 100 ventricular ectopic complexes in 24 hrs by Holter screening or any other Holter abnormalities determined by the investigator.
  6. Presence or history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome.
  7. Heart rate \<40 or >100 beats per minute (bpm).
  8. Evidence of previous myocardial infarction or any clinically significant conduction abnormality such as (including but not specific to left complete bundle branch block, AV block [2nd degree or higher], WPW syndrome). Long standing RBBB is permitted.
  9. Past or intended use of over-the-counter or prescription medication, including herbal medications, CBD-based products, PPIs or H2 antagonists within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is the longest) prior to dosing. Other concomitant medication may be considered on a case by case basis by the investigator in consultation with the medical monitor. Paracetamol is permitted (capped at ≤2 grams/day).
  10. Participation in the study that would result in loss of blood or blood products in excess of 500 mL within a 56-day period.
  11. Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  12. Current enrolment or past participation (within the last 30 days before planned first dose in this study) in any other clinical study involving an study intervention or any other type of medical research.
  13. Participants previously dosed in this study.
  14. Presence of [or HBcAb] at screening or within 3 months prior to first dose of study intervention.
  15. Positive antibody test result at screening or within 3 months prior to first dose of study intervention.
  16. Positive hepatitis C RNA (ribonucleic acid) test result at screening or within 3 months prior to first dose of study intervention.
  17. Positive pre-study drug/alcohol screen.
  18. Positive antibody test.
  19. Carbon monoxide levels indicative of smoking or more than 10 pack year history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  20. Use of known recreational drugs or drugs of abuse.
  21. Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the Investigator or GSK Medical Monitor, contraindicates participation in the study.
  22. A positive confirmation of COVID-19 infection according to local procedures.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    6 mg single ascending dose (SAD) Group

    Participants receive a 6 mg single dose of GSK4024484, in a fasted state.

    Drug: GSK4024484C

  • Experimental
    12 mg SAD Group

    Participants receive a 12 mg single dose of GSK4024484 in a fasted state.

    Drug: GSK4024484C

  • Experimental
    24 mg SAD Group

    Participants receive a 24 mg single dose of GSK4024484 in a fasted state.

    Drug: GSK4024484C

  • Experimental
    48 mg SAD Group

    Participants receive a 48 mg single dose of GSK4024484 in a fasted state.

    Drug: GSK4024484C

  • Experimental
    96 mg SAD Group

    Participants receive a 96 mg single dose of GSK4024484 in a fasted state.

    Drug: GSK4024484C

  • Experimental
    192 mg SAD Group

    Participants receive a 192 mg single dose of GSK4024484, in a fasted state.

    Drug: GSK4024484C

  • Experimental
    Food Effect Group

    Participants receive a single study dose of GSK4024484 in a fed state.

    Drug: GSK4024484C

  • Experimental
    300 mg SAD Group

    Participants receive a 300 mg single dose of GSK4024484, in a fasted state.

    Drug: GSK4024484C

  • Experimental
    400 mg SAD Group

    Participants receive a 400 mg single dose of GSK4024484, in a fasted state.

    Drug: GSK4024484C

  • Experimental
    Optional SAD Group

    Participants may be included in this group, to allow flexibility if the dose escalation needs modification or a dose level needs to be added or repeated.

    Drug: GSK4024484C

  • Placebo comparator
    Placebo SAD Group

    Participants receive placebo in a fed or fasted state.

    Drug: Placebo

  • Experimental
    150 mg multiple ascending doses (MAD) Group

    Participants receive 150 mg per day of GSK4024484 during 3 subsequent days (450 mg total).

    Drug: GSK4024484C

  • Experimental
    300 mg MAD Group

    Participants receive 300 mg per day of GSK4024484 during 3 subsequent days (900 mg total).

    Drug: GSK4024484C

  • Experimental
    Optional MAD Group

    Participants may be included in this group, to allow flexibility if the dose escalation needs modification or a dose level needs to be added or repeated.

    Drug: GSK4024484C

  • Placebo comparator
    Placebo MAD Group

    Participants receive placebo during 3 subsequent days.

    Drug: Placebo

Interventions

  • DrugGSK4024484C

    Doses administrated orally with 240 mL of water.

  • DrugPlacebo

    Doses administrated orally with 240 mL of water.

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting serious adverse events (SAEs) after single ascending doses

    An SAE is defined as any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or an abnormal partner pregnancy outcome.

    Time frame: From the signing of the informed consent (Day -2) until the follow up contact (Day 38 +/- 3 days post dose)

  2. Percentage of participants reporting SAEs by severity after single ascending doses

    Mild SAE = a type of adverse event (AE) that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate SAE = a type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe SAE = a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: From the signing of the informed consent (Day -2) until the follow up contact (Day 38 +/- 3 days post dose)

  3. Percentage of participants reporting SAEs after multiple ascending doses

    An SAE is defined as any untoward medical occurrence that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or an abnormal partner pregnancy outcome.

    Time frame: From the signing of the informed consent (Day -2) until the follow up contact (Day 40 +/- 3 days post dose)

  4. Percentage of participants reporting SAEs by severity after multiple ascending doses

    Mild SAE = a type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate SAE = a type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe SAE = a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: From the signing of the informed consent (Day -2) until the follow up contact (Day 40 +/- 3 days post dose)

  5. Percentage of participants reporting non-serious AEs after single ascending doses

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 38 +/- 3 days post dose)

  6. Percentage of participants reporting non-serious AEs by severity after single ascending doses

    Mild AE = a type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate AE = a type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe AE = a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 38 +/- 3 days post dose)

  7. Percentage of participants reporting non-serious AEs after multiple ascending doses

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: From first study dose administration (Day 1) until the follow up contact (Day 40 +/- 3 days post dose)

  8. Percentage of participants reporting non-serious AEs by severity after multiple ascending doses

    Mild AE = a type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate AE = a type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. Severe AE = a type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: From first study dose administration (Day 1) until the follow up contact (Day 40 +/- 3 days post dose)

Secondary outcomes

  1. Part A: Area under the plasma drug concentration versus time curve from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)] of GSK4024484C following single ascending doses in fasting conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  2. Part A: Area under the plasma drug concentration versus time curve from zero (pre-dose) extrapolated to infinite time [AUC(0-∞)] of GSK4024484C following single ascending doses in fasting conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  3. Part A: Maximum observed plasma drug concentration (Cmax) of GSK4024484C following single ascending doses in fasting conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  4. Part A: Time to maximum observed plasma drug concentration (Tmax) of GSK4024484C following single ascending doses in fasting conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  5. Part A: Apparent terminal half-life (t1/2) of GSK4024484C following single ascending doses in fasting conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  6. Part B: AUC(0-t) of GSK4024484C following multiple ascending doses in fasting conditions

    Time frame: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)

  7. Part B: AUC(0-∞) of GSK4024484C following multiple ascending doses in fasting conditions

    Time frame: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)

  8. Part B: Cmax of GSK4024484C following multiple ascending doses in fasting conditions

    Time frame: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)

  9. Part B: Tmax of GSK4024484C following multiple ascending doses in fasting conditions

    Time frame: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)

  10. Part B: t1/2 of GSK4024484C following multiple ascending doses in fasting conditions

    Time frame: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)

  11. Part B: Area under the plasma drug concentration versus time curve from zero to time of trough plasma concentration [AUC(0-tau)] of GSK4024484C following multiple ascending doses in fasting conditions

    Time frame: Part B: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)

  12. Part B: Trough plasma concentration (Ctau) of GSK4024484C following multiple ascending doses in fasting conditions

    Time frame: From first study dose administration (Day 1) until the follow up contact (Day 33 +/- 1 day post dose)

  13. Part A: AUC(0-t) of GSK4024484C following single ascending doses in fed conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  14. Part A: AUC(0-∞) of GSK4024484C following single ascending doses in fed conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  15. Part A: Cmax of GSK4024484C following single ascending doses in fed conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  16. Part A: Tmax of GSK4024484C following single ascending doses in fed conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  17. Part A: t1/2 of GSK4024484C following single ascending doses in fed conditions

    Time frame: From study dose administration (Day 1) until the follow up contact (Day 29 +/- 1 day post dose)

  18. Part B: Observed accumulation ratio (R) of GSK4024484 based on AUC(Ro) following multiple ascending doses

    Time frame: At Day 1 and at Day 3

  19. Part B: Observed accumulation ratio (R) of GSK4024484 based on Cmax(RCmax) following multiple ascending doses

    Time frame: At Day 1 and at Day 3

07

Study locations

1 site
  • GSK Investigational Site
    Cambridge, CB2 0GG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://d3l8i7lo48obsd.cloudfront.net/gsk-patient-level-data-sharing-july2025-1-Bgwa1UthxvluYbWYTThw.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · d3l8i7lo48obsd.cloudfront.net

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Jun 2026, 30 months.

Of 49 phase 1 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 18. This study's 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 14, 2023
StartActual
Dec 11, 2023
Primary completionActual
Jun 16, 2026
CompletionActual
Jun 16, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06171113
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Dec 11, 2023
Primary completion
Jun 16, 2026
Completion
Jun 16, 2026
Last update
Jul 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion